Presentations TAT 2017

To view presentations in PDF format, click on the lecture title. Note that not all speakers have given their consent for release of their presentation.

Monday, March 6, 2017

Plenary Session 1: Opening Ceremony

O1.1 TAT 2017 Honorary Award Invited Lecture: Immunologic Checkpoint Blockade: Exploring Combinations and Mechanisms
Jedd Wolchok, Memorial Sloan Kettering Cancer Center, New York, NY, USA

O1.2 Keynote Lecture: Positioning Immune checkpoint blockade within the systemic anti-cancer armamentarium
Alexander Eggermont, Institut Gustave Roussy, Villejuif, France

Plenary Session 2: Immuno-oncology (1): Novel combinations, novel approaches

O2.2 Combining IO with IO: rationale and clinical perspectives
Ignacio Melero, University of Navarra, Navarra, Spain

O2.3 Clinical stage: Immune Design (TLR-4 agonist)
Carlos Paya, Immune Design, South San Francisco, CA, USA

Plenary Session 3: Phase 1 Studies – Completed or in progress (miscellaneous drugs & targets)

O3.1 A Phase 1/1b, first-in-human study of IPI-549, a PI3K-? inhibitor and myeloid targeting agent, as monotherapy and in combination with nivolumab in patients with advanced solid tumors
Anthony Tolcher, South Texas Accelerated Research Therapeutics, San Antonio, TX, USA

O3.4 Phase IB study of CC-122 and obinutuzumab in relapsed or refractory diffuse large B-cell lymphoma and indolent non-Hodgkin lymphoma
Jean-Marie Michot, Institut Gustave Roussy, Villejuif, France

O3.5 Preliminary evidence of clinical activity with tipifarnib in squamous cell carcinomas of the head & neck (SCCHN) with HRAS mutations.
Alan Ho, Memorial Sloan Kettering Cancer Center, New York, NY, USA

Tuesday, March 7, 2017

Plenary Session 5: Immuno-oncology (2): Novel immune modulators

O5.2 Bugs as Drugs, on the way to becoming a reality
Laura Rosa Brunet, Immodulon Therapeutics, Uxbridge, United Kingdom

O5.3 Combining immune checkpoints with cytotoxic chemotherapies
François Ghiringhelli, Centre Georges-François Leclerc, Dijon Cedex, France

O5.4 Boosting Immunity and The Cancer Immune Setpoint
Daniel Chen, Genentech, San Francisco, CA, USA

Plenary Session 6: Targeting the cell cycle

O6.1 The Targeting of CDK4/6 Signaling Pathway: Defining a Biomarker for Response
Gary Schwartz, Columbia University, New York, NY, USA

O6.3 Exploiting the potential of ATR inhibitors
Timothy Yap, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Plenary Session 7: Targeted drug delivery: Next-generation antibody-drug conjugates and nanomedicines

O7.1 Abbvie/CytomX program on ADCs
Rachel Humphrey, CytomX Therapeutics, South San Francisco, CA, USA

O7.2 DCs with diverse payloads of tumor-killing agents
Donald A. Bergstrom, Mersana Therapeutics, Cambridge, MA, USA

O7.3 Rovalpituzumab tesirine (Rova-T)
Giuseppe Giaccone, Georgetown University, Washington, DC, USA

O7.5 Paving a Novel Approach to Developing Anticancer Combinations through Tumor-Targeting Nanomedicines
Lawrence D. Mayer, Jazz Pharmaceuticals, Vancouver, Canada

Plenary Session 8: Clinical genomic profiling in early-phase clinical studies

O8.1 Educational introduction: Genomic profiling techniques. Their pros and cons.
Maria Arcila, Memorial Sloan Kettering Cancer Center, New York, NY, USA

O8.2 Predictive biomarker evaluations and immunophenotyping in immunotherapy: the INSPIRE clinical trial
Derek Clouthier, Princess Margaret Cancer Centre / University Health Network, Toronto, Canada


Wednesday, March 8, 2017

Plenary Session 9: Targeting cancer metabolism

O9.2 Metabolic targets in renal cell cancer
Brian Shuch, Yale University, New Haven, CT, USA

O9.4 Liver-X-Receptor Inverse Agonists as Anti-Cancer Therapies that Targets the Warburg Effect and Lipogenesis
Colin Flaveny, Saint Louis University, Saint Louis, MO, USA

Plenary Session 10: Miscellaneous drugs, targets and methods

O10.2 Epigenetic priming for immunotherapy: what progress has there been in the promise?
Nilofer Azad, Johns Hopkins University, Baltimore, MD, USA

Plenary Session 11: DNA-targeted therapies

O11.1 Tumor DNA Targeting: It is time to wake up
Yves Pommier, National Cancer Institute, Bethesda, MD, USA

Plenary Session 12: New targets in the androgen receptor pathway

O12.1 Precision medicine in prostate cancer: Androgen Receptors pathway, biology and therapeutics
Bertrand Tombal, Cliniques universitaires Saint Luc, Brussels, Belgium